Literature DB >> 7752193

Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.

G M Ksander1, R D Ghai, R deJesus, C G Diefenbacher, A Yuan, C Berry, Y Sakane, A Trapani.   

Abstract

The synthesis of three series of dicarboxylic acid dipeptide neutral endopeptidase 24.11 (NEP) inhibitors is described. In particular, the amino butyramide 21a exhibited potent NEP inhibitory activity (IC50 = 5.0 nM) in vitro and in vivo. Blood levels of 21a were determined using an ex vivo method by measuring plasma inhibitory activity in conscious rats, mongrel dogs, and cynomolgus monkeys. Free drug concentrations were 10-1500 times greater than the inhibitory constant for NEP over the course of a 6 h experiment. A good correlation of free drug concentrations was obtained when comparing values determined by the ex vivo analysis to those calculated from direct HPLC measurements. Plasma atrial natriuretic factor (exogenous) levels were elevated in rats and dogs after oral administration of 19a. Urinary volume and urinary sodium excretion were also potentiated in anesthetized dogs treated with 21a.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752193     DOI: 10.1021/jm00010a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

2.  Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.

Authors:  Toshio Kawanami; Rajeshri G Karki; Emma Cody; Qian Liu; Guiqing Liang; Gary M Ksander; Dean F Rigel; Nikolaus Schiering; Yongjin Gong; Gary M Coppola; Yuki Iwaki; Robert Sun; Alan Neubert; Li Fan; Sara Ingles; Allan D'Arcy; Frederic Villard; Paul Ramage; Arco Y Jeng; Jennifer Leung-Chu; Jing Liu; Michael Beil; Fumin Fu; Wei Chen; Frederic Cumin; Christian Wiesmann; Muneto Mogi
Journal:  ACS Med Chem Lett       Date:  2020-01-27       Impact factor: 4.345

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 4.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

Review 5.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

6.  Sacubitril-Valsartan Increases Ultrafiltration in Patients Undergoing Peritoneal Dialysis: A Short-Term Retrospective Self-Controlled Study.

Authors:  Fen Zhang; Tingting Zhang; Sisi Yang; Di Wang; Qianqian Zhuo; Xianhui Qin; Nirong Gong; Jun Ai
Journal:  Front Med (Lausanne)       Date:  2022-06-03

Review 7.  Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.

Authors:  Erik H Howell; Scott J Cameron
Journal:  Cardiol J       Date:  2016-09-26       Impact factor: 2.737

Review 8.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Authors:  Scott A Hubers; Nancy J Brown
Journal:  Circulation       Date:  2016-03-15       Impact factor: 29.690

Review 9.  Potential Expanded Indications for Neprilysin Inhibitors.

Authors:  Elizabeth Riddell; Justin M Vader
Journal:  Curr Heart Fail Rep       Date:  2017-04

10.  Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.

Authors:  Jian Shi; Xinwen Wang; Jenny Nguyen; Audrey H Wu; Barry E Bleske; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2016-01-27       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.